Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Bone Density"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 84006

Starter badań:

Tytuł:
Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
Autorzy:
Hu M; Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Zhang Y; Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Guo J; Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Guo C; Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yang X; Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Ma X; Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xu H; Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xiang S; Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Pokaż więcej
Źródło:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Jul 12; Vol. 14, pp. 1188969. Date of Electronic Publication: 2023 Jul 12 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Systematic Review
MeSH Terms:
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporosis*/chemically induced
Humans ; Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use
Raport
Szczegóły
Tytuł:
Effects of genistein aglycone in glucocorticoid induced osteoporosis: A randomized clinical trial in comparison with alendronate.
Autorzy:
Squadrito F; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy. Electronic address: .
Imbalzano E; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Rottura M; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Arcoraci V; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Pallio G; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Catalano A; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Atteritano M; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Irrera N; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Mannino F; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Squadrito G; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Vaccaro M; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Irrera P; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Pirrotta I; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Bitto A; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Pokaż więcej
Źródło:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Jul; Vol. 163, pp. 114821. Date of Electronic Publication: 2023 May 09.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/chemically induced
Osteoporosis, Postmenopausal*/drug therapy
Humans ; Female ; Alendronate/therapeutic use ; Glucocorticoids/pharmacology ; Genistein/pharmacology ; Genistein/therapeutic use ; Bone Density ; Double-Blind Method
Czasopismo naukowe
Szczegóły
Tytuł:
Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis.
Autorzy:
Beaudart C; WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium, Avenue Hippocrate 13, CHU Bât B23, 4000, Liège, Belgium.
Demonceau C; WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium, Avenue Hippocrate 13, CHU Bât B23, 4000, Liège, Belgium.
Sabico S; Biochemistry Department, College of Science, Chair for Biomarkers of Chronic Diseases, King Saud University, Riyadh, 11451, Saudi Arabia.
Veronese N; Geriatric Unit, Department of Internal Medicine, Geriatrics Section, University of Palermo, via del Vespro, 141, 90127, Palermo, Italy.
Cooper C; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK.
Harvey N; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK.
Fuggle N; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK.
Bruyère O; WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium, Avenue Hippocrate 13, CHU Bât B23, 4000, Liège, Belgium.
Rizzoli R; Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Hopitaux Universitaires Geneve, Geneva, Switzerland. .
Reginster JY; WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium, Avenue Hippocrate 13, CHU Bât B23, 4000, Liège, Belgium.
Pokaż więcej
Źródło:
Aging clinical and experimental research [Aging Clin Exp Res] 2023 Sep; Vol. 35 (9), pp. 1789-1806. Date of Electronic Publication: 2023 Jul 03.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Fractures, Bone*
Male ; Female ; Humans ; Bone Density ; Diphosphonates/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Evaluation of the efficacy and tolerability of alendronate versus denosumab in kidney transplant patients with reduced bone mineral density.
Autorzy:
Sayed SA; Clinical Pharmacy Department, Faculty of Pharmacy, Nahda University, Beni-suef, Egypt.
El Wakeel LM; Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Elseasi AM; Internal Medicine and Nephrology Department, National Institute of Urology and Nephrology, Cairo, Egypt.
Shawki MA; Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Pokaż więcej
Źródło:
Pharmacotherapy [Pharmacotherapy] 2023 Sep; Vol. 43 (9), pp. 904-912. Date of Electronic Publication: 2023 Jun 22.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Bone Density Conservation Agents*/adverse effects
Kidney Transplantation*/adverse effects
Humans ; Alendronate/adverse effects ; Denosumab/adverse effects ; Bone Density ; Calcium/pharmacology ; Quality of Life ; Vitamin D/pharmacology
Czasopismo naukowe
Szczegóły
Tytuł:
Osteoporosis medication adherence tools: a systematic review.
Autorzy:
Hesari E; Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.; School of Public Health, Department of Epidemiology and Biostatistics, Tehran University of Medical Science, Tehran, Iran.
Sanjari M; Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. .
Mansourzadeh MJ; Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.; Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fahimfar N; Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.; School of Public Health, Department of Epidemiology and Biostatistics, Tehran University of Medical Science, Tehran, Iran.
Khalagi K; Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.; Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ghazbani A; Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.; School of Public Health, Department of Epidemiology and Biostatistics, Tehran University of Medical Science, Tehran, Iran.
Ostovar A; Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.; Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Fotouhi A; School of Public Health, Department of Epidemiology and Biostatistics, Tehran University of Medical Science, Tehran, Iran.
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2023 Sep; Vol. 34 (9), pp. 1535-1548. Date of Electronic Publication: 2023 Jun 08.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Fractures, Bone*/drug therapy
Humans ; Medication Adherence ; Bone Density
Czasopismo naukowe
Szczegóły
Tytuł:
Computed tomography density changes of bone metastases after concomitant denosumab.
Autorzy:
Mallio CA; Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy. .; Research Unit of Radiology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy. .
Greco F; U.O.C. Diagnostica per Immagini Territoriale Aziendale, Cittadella della Salute Azienda Sanitaria Locale di Lecce, Lecce, Italy.
Gaudino F; U.O.S.D Diagnostica per Immagini Emergenza Urgenza, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy.
Beomonte Zobel B; Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy.; Research Unit of Radiology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy.
Quattrocchi CC; Centre for Medical Sciences - CISMed, University of Trento, Trento, Italy.
Pokaż więcej
Źródło:
Skeletal radiology [Skeletal Radiol] 2023 Aug; Vol. 52 (8), pp. 1567-1575. Date of Electronic Publication: 2023 Mar 24.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Neoplasms*/diagnostic imaging
Bone Neoplasms*/drug therapy
Bone Neoplasms*/secondary
Bone Density Conservation Agents*/therapeutic use
Adult ; Humans ; Denosumab/therapeutic use ; Retrospective Studies ; Tomography, X-Ray Computed/methods ; Bone Density
Czasopismo naukowe
Szczegóły
Tytuł:
Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone Health.
Autorzy:
Kostenuik PJ; Phylon Pharma Services; School of Dentistry (Adjunct), University of Michigan, Newbury Park, CA, USA. .
Binkley N; Osteoporosis Clinical Research Program, University of Wisconsin, Madison, WI, USA.
Anderson PA; Department of Orthopedics and Rehabilitation, University of Wisconsin, Madison, WI, USA.
Pokaż więcej
Źródło:
Current osteoporosis reports [Curr Osteoporos Rep] 2023 Aug; Vol. 21 (4), pp. 386-400. Date of Electronic Publication: 2023 Jun 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/complications
Osteoporosis*/drug therapy
Osteoporosis*/chemically induced
Osteoporotic Fractures*/prevention & control
Humans ; Bone Density ; Teriparatide/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Nonresponder Considerations for Romosozumab Treatment.
Autorzy:
Tominaga A; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan. .
Wada K; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Okazaki K; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Nishi H; Hasuda Hospital, Saitama, Japan.
Terayama Y; Hasuda Hospital, Saitama, Japan.
Shimamoto S; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Kodama Y; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Kato Y; Kita Shinagawa 3rd Hospital, Tokyo, Japan.
Pokaż więcej
Źródło:
Calcified tissue international [Calcif Tissue Int] 2023 Aug; Vol. 113 (2), pp. 157-165. Date of Electronic Publication: 2023 May 03.
Typ publikacji:
Observational Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/drug therapy
Osteoporosis*/chemically induced
Osteoporosis, Postmenopausal*
Humans ; Female ; Bone Density ; Lumbar Vertebrae
Czasopismo naukowe
Szczegóły
Tytuł:
Effectiveness of Weekly Teriparatide Injection in Postmenopausal Patients with Hip Fractures.
Autorzy:
Lee SY; Biomedical Research Institute, Gyeongsang National University Hospital, Jinju, Korea.
Seo MS; Department of Orthopaedic Surgery, Gyeongsang National University Hospital, Jinju, Korea.
Yoo JI; Department of Orthopaedic Surgery, Gyeongsang National University Hospital, Jinju, Korea.
Pokaż więcej
Źródło:
Clinics in orthopedic surgery [Clin Orthop Surg] 2023 Aug; Vol. 15 (4), pp. 552-559. Date of Electronic Publication: 2023 Feb 27.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Osteoporosis, Postmenopausal*/chemically induced
Hip Fractures*/drug therapy
Hip Fractures*/surgery
Female ; Humans ; Teriparatide/therapeutic use ; Postmenopause ; Bone Density
Czasopismo naukowe
Szczegóły
Tytuł:
Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency.
Autorzy:
Gronskaya S; Endocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.
Belaya Z; Endocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia. .
Rozhinskaya L; Endocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.
Mamedova E; Endocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.
Vorontsova M; Endocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.; Lomonosov Moscow State University, Laboratory for Molecular Endocrinology, Moscow, Russia.
Solodovnikov A; Ural State Medical Academy, Ekaterinburg, Russia.
Golounina O; Sechenov First Moscow State Medical University, Moscow, Russia.
Melnichenko G; Endocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.
Pokaż więcej
Źródło:
Endocrine [Endocrine] 2023 Aug; Vol. 81 (2), pp. 368-378. Date of Electronic Publication: 2023 May 03.
Typ publikacji:
Journal Article
MeSH Terms:
Hyperparathyroidism, Primary*/complications
Hyperparathyroidism, Primary*/drug therapy
Osteoporosis*/etiology
Osteoporosis*/chemically induced
Osteoporosis, Postmenopausal*/drug therapy
Bone Density Conservation Agents*/adverse effects
Renal Insufficiency*/complications
Renal Insufficiency*/chemically induced
Renal Insufficiency, Chronic*/complications
Renal Insufficiency, Chronic*/drug therapy
Humans ; Female ; Middle Aged ; Aged ; Denosumab/therapeutic use ; Calcium ; Longitudinal Studies ; Retrospective Studies ; Bone Density
Czasopismo naukowe
Szczegóły
Tytuł:
Treatment of osteoporosis with denosumab in patients with decreased kidney function.
Autorzy:
Svendsen OL; Department of Endocrinology, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Ebba Lunds Vej 44, Entrance 60, ground floor, DK-2400, Copenhagen, NV, Denmark. .; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. .
Pokaż więcej
Źródło:
Archives of osteoporosis [Arch Osteoporos] 2023 Jul 26; Vol. 18 (1), pp. 104. Date of Electronic Publication: 2023 Jul 26.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Hypocalcemia*/chemically induced
Hypocalcemia*/complications
Hypocalcemia*/drug therapy
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/etiology
Osteoporotic Fractures*/drug therapy
Osteoporotic Fractures*/prevention & control
Humans ; Middle Aged ; Aged ; Aged, 80 and over ; Denosumab/adverse effects ; Retrospective Studies ; Bone Density ; Kidney
Czasopismo naukowe
Szczegóły
Tytuł:
Approaches to reduce periprosthetic bone resorption after total hip arthroplasty.
Autorzy:
Mori Y; Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan. .
Mori N; Department of Radiology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan.
Pokaż więcej
Źródło:
Journal of bone and mineral metabolism [J Bone Miner Metab] 2023 Jul; Vol. 41 (4), pp. 575-576. Date of Electronic Publication: 2023 Apr 08.
Typ publikacji:
Letter
MeSH Terms:
Arthroplasty, Replacement, Hip*/adverse effects
Bone Density Conservation Agents*
Bone Resorption*/prevention & control
Humans ; Risedronic Acid ; Bone Density
Opinia redakcyjna
Szczegóły
Tytuł:
Denosumab effect on bone mineral density and urinary-NTX in breast cancer patients receiving aromatase inhibitors.
Autorzy:
Shibata M; Department of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan. .; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. .
Okumura M; Department of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Kawano S; Department of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Noda H; Department of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Toyota C; Department of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Mizuno Y; Department of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi-City, Mie, 510-8567, Japan.
Pokaż więcej
Źródło:
Journal of bone and mineral metabolism [J Bone Miner Metab] 2023 Jul; Vol. 41 (4), pp. 567-574. Date of Electronic Publication: 2023 May 29.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Bone Density Conservation Agents*/therapeutic use
Humans ; Middle Aged ; Aged ; Aged, 80 and over ; Female ; Bone Density ; Denosumab/adverse effects ; Aromatase Inhibitors/adverse effects ; Retrospective Studies ; Lumbar Vertebrae ; Biomarkers
Czasopismo naukowe
Szczegóły
Tytuł:
Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study.
Autorzy:
Liebich G; Faculty of Biology and Medicine, University of Lausanne, 1015 Lausanne, Switzerland.
Lamy O; Interdisciplinary Center for Bone Diseases, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; Service of Internal Medicine, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Aubry-Rozier B; Interdisciplinary Center for Bone Diseases, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Gonzalez-Rodriguez E; Interdisciplinary Center for Bone Diseases, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. Electronic address: .
Pokaż więcej
Źródło:
Bone [Bone] 2023 Jul; Vol. 172, pp. 116764. Date of Electronic Publication: 2023 Apr 14.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Spinal Fractures*
Bone Resorption*/drug therapy
Humans ; Female ; Middle Aged ; Aged ; Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Diphosphonates/therapeutic use ; Lumbar Vertebrae
Czasopismo naukowe
Szczegóły
Tytuł:
Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective.
Autorzy:
Yamasaki S; Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Oita, 874-0838, Japan. .; Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, 810-0065, Japan. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2023 Jul; Vol. 102 (7), pp. 1645-1656. Date of Electronic Publication: 2023 May 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Purpura, Thrombocytopenic, Idiopathic*/drug therapy
Osteoporosis*/drug therapy
Bone Density Conservation Agents*/adverse effects
Humans ; Aged ; Diphosphonates/adverse effects ; Glucocorticoids/therapeutic use ; Bone Density ; Prednisolone/adverse effects
Czasopismo naukowe
Szczegóły
Tytuł:
Recent advance of small-molecule drugs for clinical treatment of osteoporosis: A review.
Autorzy:
Zhang JY; College of Chemistry and Chemical Engineering, Zhengzhou Normal University, Zhengzhou, 450044, China.
Zhong YH; Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, 130033, China; Department of Orthopedics, The Fourth Affiliated Hospital of Guangxi Medical University/Liu-Zhou Worker's Hospital, Liuzhou, Guangxi, 545005, China.
Chen LM; Department of Orthopedics, The Fourth Affiliated Hospital of Guangxi Medical University/Liu-Zhou Worker's Hospital, Liuzhou, Guangxi, 545005, China.
Zhuo XL; Department of Orthopedics, The Fourth Affiliated Hospital of Guangxi Medical University/Liu-Zhou Worker's Hospital, Liuzhou, Guangxi, 545005, China.
Zhao LJ; The Rogel Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, United States. Electronic address: .
Wang YT; First People's Hospital of Shangqiu, Henan Province, Shangqiu, 476100, China; Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, 130033, China. Electronic address: .
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2023 Nov 05; Vol. 259, pp. 115654. Date of Electronic Publication: 2023 Jul 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Osteoporosis, Postmenopausal*/drug therapy
Osteoporosis*/drug therapy
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Female ; Humans ; Bone Density ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Selective Estrogen Receptor Modulators/pharmacology
Czasopismo naukowe
Szczegóły
Tytuł:
Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
Autorzy:
Dito G; Endocrinology and Diabetology Service, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
Lugaresi M; Endocrinology and Diabetology Service, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.; Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Degradi C; Endocrinology and Diabetology Service, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.; Department of Medical and Surgical Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Guabello G; Endocrinology and Diabetology Service, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
Longhi M; Rheumatology Unit, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
Corbetta S; Bone Metabolism Diseases and Diabetes Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy. .; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. .
Pokaż więcej
Źródło:
Endocrine [Endocrine] 2023 Oct; Vol. 82 (1), pp. 181-189. Date of Electronic Publication: 2023 Jul 04.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/drug therapy
Osteoporosis*/chemically induced
Fractures, Bone*/chemically induced
Male ; Female ; Humans ; Aged ; Middle Aged ; Zoledronic Acid/therapeutic use ; Zoledronic Acid/pharmacology ; Teriparatide/adverse effects ; Bone Density ; Denosumab/adverse effects ; Retrospective Studies ; Diphosphonates/adverse effects ; Bone Remodeling ; Biomarkers
Czasopismo naukowe
Szczegóły
Tytuł:
Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.
Autorzy:
Tsai YL; Department of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Wu CH; Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Institute of Gerontology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Li CC; Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Shih CA; Department of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chang YF; Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Hwang JS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Tai TW; Department of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .; Skeleton Materials and Biocompatibility Core Lab, Research Center of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2023 Oct; Vol. 34 (10), pp. 1783-1791. Date of Electronic Publication: 2023 Jul 19.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporotic Fractures*/prevention & control
Osteoporotic Fractures*/surgery
Osteoporotic Fractures*/drug therapy
Hip Fractures*/drug therapy
Hip Fractures*/surgery
Hip Fractures*/complications
Humans ; Denosumab/therapeutic use ; Cohort Studies ; Duration of Therapy ; Bone Density ; Medication Adherence
Czasopismo naukowe
Szczegóły
Tytuł:
Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
Autorzy:
Khan AA; McMaster University, Hamilton, Ontario, Canada. .
AbuAlrob H; McMaster University, Hamilton, Ontario, Canada.
M'Hiri I; Bone Research and Education Centre, Oakville, Ontario, Canada.
Ali DS; McMaster University, Hamilton, Ontario, Canada.
Dandurand K; McMaster University, Hamilton, Ontario, Canada.
Said H; McMaster University, Hamilton, Ontario, Canada.
Alkassem H; McMaster University, Hamilton, Ontario, Canada.
Hakami Y; McMaster University, Hamilton, Ontario, Canada.
Hweija I; McMaster University, Hamilton, Ontario, Canada.
Iqbal S; Bone Research and Education Centre, Oakville, Ontario, Canada.
Romanovschi M; Bone Research and Education Centre, Oakville, Ontario, Canada.
Mehmood S; Bone Research and Education Centre, Oakville, Ontario, Canada.
Zariffeh H; Bone Research and Education Centre, Oakville, Ontario, Canada.
Guyatt G; McMaster University, Hamilton, Ontario, Canada.
Ibrahim Q; McMaster University, Hamilton, Ontario, Canada.
Brignardello-Petersen R; McMaster University, Hamilton, Ontario, Canada.
Syed HI; McMaster University, Hamilton, Ontario, Canada.; Bone Research and Education Centre, Oakville, Ontario, Canada.
Pokaż więcej
Źródło:
Endocrine [Endocrine] 2023 Jun; Vol. 80 (3), pp. 647-657. Date of Electronic Publication: 2023 Apr 25.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Osteoporosis, Postmenopausal*/drug therapy
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Fractures, Bone*/prevention & control
Humans ; Female ; Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Postmenopause
Czasopismo naukowe
Szczegóły
Tytuł:
Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.
Autorzy:
Oue T; Department of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.
Shimizu T; Department of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, 060-8638, Japan. .
Asano T; Department of Orthopedic Surgery, KKR Sapporo Medical Center, Sapporo, Japan.
Shimodan S; Department of Orthopedic Surgery, Kushiro City General Hospital, Kushiro, Japan.
Ishizu H; Department of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.
Arita K; Department of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.
Iwasaki N; Department of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.
Pokaż więcej
Źródło:
Calcified tissue international [Calcif Tissue Int] 2023 Jun; Vol. 112 (6), pp. 683-690. Date of Electronic Publication: 2023 Apr 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Female ; Humans ; Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; East Asian People ; Postmenopause ; Tartrate-Resistant Acid Phosphatase ; Zoledronic Acid/pharmacology ; Drug Substitution
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 84006

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies